DifGen Pharmaceuticals Achieves Crucial FDA Approval for Generic Mesalamine Capsules
In a significant advancement for patient care, DifGen Pharmaceuticals LLC, a specialty generic pharmaceutical company based in the United States, has announced its recent FDA approval for the generic version of Mesalamine Extended-Release Capsules, available in 250 mg and 500 mg strengths. Notably, the 250 mg variation has been granted a Competitive Generic Therapy (CGT) designation, highlighting its importance in the market.
The FDA's approval underscores DifGen's commitment to expanding access to high-quality pharmaceuticals that are not just affordable, but also effective. The approved Mesalamine products are therapeutically equivalent (AB-rated) to the reference drug, PENTASA®, which is widely recognized for its role in treating conditions like ulcerative colitis. This milestone not only showcases DifGen’s capabilities in navigating complex regulatory pathways, but it also reflects their rigorous commitment to excellence in pharmaceutical development.
"When Santa and I founded DifGen, we envisioned 'Difficult and Differentiated Generics.' This approval embodies that vision, allowing us to expand our portfolio and bring more treatment options to patients navigating inflammatory bowel diseases," shared Ramandeep Singh Jaj, Founder and Co-CEO of DifGen Pharmaceuticals. The company has established itself as a leader in developing complex generics, navigating challenges that often come with innovative drug formulations.
The scientific and clinical expertise underlying this approval is impressive. Dr. Santhanakrishnan Srinivasan, also a founder and Co-CEO, noted the inherent pharmacokinetic challenges faced in the development of Mesalamine, from managing inter-subject variability to ensuring product effectiveness through stringent manufacturing processes. The approval reflects the hard work of their scientific affairs team, who meticulously addressed these challenges.
DifGen's efforts to develop complex formulations align with its mission to ensure that essential medicines are accessible to patients across the United States. Their portfolio of products is diverse, covering various dosage forms and backed by comprehensive expertise in product development, quality assurance, and regulatory compliance. This FDA approval not only strengthens their product lineup but reinforces their dedication to innovation and health equity.
As healthcare continues to advance and the demand for effective treatments grows, companies like DifGen play a pivotal role in ensuring that patients have access to reliable options. With the approval of the Mesalamine Extended-Release Capsules, DifGen Pharmaceuticals is set to make a noteworthy impact in the pharmaceutical landscape, alleviating the burdens faced by those with chronic conditions and fortifying the accessibility of needed medications.
For further details on their products or to read more about their upcoming ventures, you can visit DifGen's official website at www.difgen.com. Additionally, inquiries regarding this press release can be directed to Roberta Loomar, Global General Counsel, at +19546051796.
The FDA's approval underscores DifGen's commitment to expanding access to high-quality pharmaceuticals that are not just affordable, but also effective. The approved Mesalamine products are therapeutically equivalent (AB-rated) to the reference drug, PENTASA®, which is widely recognized for its role in treating conditions like ulcerative colitis. This milestone not only showcases DifGen’s capabilities in navigating complex regulatory pathways, but it also reflects their rigorous commitment to excellence in pharmaceutical development.
"When Santa and I founded DifGen, we envisioned 'Difficult and Differentiated Generics.' This approval embodies that vision, allowing us to expand our portfolio and bring more treatment options to patients navigating inflammatory bowel diseases," shared Ramandeep Singh Jaj, Founder and Co-CEO of DifGen Pharmaceuticals. The company has established itself as a leader in developing complex generics, navigating challenges that often come with innovative drug formulations.
The scientific and clinical expertise underlying this approval is impressive. Dr. Santhanakrishnan Srinivasan, also a founder and Co-CEO, noted the inherent pharmacokinetic challenges faced in the development of Mesalamine, from managing inter-subject variability to ensuring product effectiveness through stringent manufacturing processes. The approval reflects the hard work of their scientific affairs team, who meticulously addressed these challenges.
DifGen's efforts to develop complex formulations align with its mission to ensure that essential medicines are accessible to patients across the United States. Their portfolio of products is diverse, covering various dosage forms and backed by comprehensive expertise in product development, quality assurance, and regulatory compliance. This FDA approval not only strengthens their product lineup but reinforces their dedication to innovation and health equity.
As healthcare continues to advance and the demand for effective treatments grows, companies like DifGen play a pivotal role in ensuring that patients have access to reliable options. With the approval of the Mesalamine Extended-Release Capsules, DifGen Pharmaceuticals is set to make a noteworthy impact in the pharmaceutical landscape, alleviating the burdens faced by those with chronic conditions and fortifying the accessibility of needed medications.
For further details on their products or to read more about their upcoming ventures, you can visit DifGen's official website at www.difgen.com. Additionally, inquiries regarding this press release can be directed to Roberta Loomar, Global General Counsel, at +19546051796.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.